Clinical phenotypes and age-related differences in SGLT2 inhibitor-associated ketoacidosis: A nationwide pharmacovigilance case-series study
Year: 2026
Type: article
Study design: Observational Study
Abstract: With the expanding use of sodium-glucose cotransporter 2 inhibitors, pharmacovigilance data can help characterize rare but serious adverse drug reactions such as diabetic ketoacidosis. To describe the clinical spectrum and age-related differences in sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis and identify distinct clinical presentation patterns using the French Pharmacovigilance Database. We conducted a retrospective nationwide case-series study including all expert-adjudicated reports of sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis recorded in the French Pharmacovigilance Database up to December 31, 2025. Clinical characteristics were compared between patients aged < 65 and ≥ 65 years. Unsupervised clustering was used to identify clinical presentation patterns. Among 299 reports screened, 242 expert-adjudicated cases of ketoacidosis were included (median age 67 years [interquartile range 57–76]; 43% women), of which 88 (36%) fulfilled all three 2024 ADA/EASD diagnostic domains. Euglycemic DKA occurred in 64/165 patients with available blood glucose data (39%), moderate-to-severe metabolic acidosis in 107/177 patients with available pH data (60%), and 100/240 patients with available ICU data (42%) were admitted to an ICU. Three clinical presentation patterns were identified: (1) a fasting-related phenotype characterized by gastrointestinal symptoms and fasting; (2) a perioperative phenotype associated with recent surgery; and (3) an infection-related phenotype characterized by infection, neurological symptoms, and falls, predominantly affecting older patients. Neither moderate-to-severe acidosis nor ICU admission differed significantly between age groups. Sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis shows heterogeneous presentations in routine practice. Older adults more often presented with atypical manifestations, whereas younger patients more often exhibited gastrointestinal symptoms. In older adults receiving sodium-glucose cotransporter 2 inhibitors, ketoacidosis should be considered when infection, neurological symptoms, or falls occur, even in the absence of gastrointestinal symptoms.
Institutions: Inserm, Université de Poitiers, Centre Hospitalier Universitaire de Poitiers, Centre Hospitalier Universitaire de Limoges, Centre Hospitalier Universitaire de Montpellier, Centre Hospitalier Universitaire de Saint-Étienne, Centre Hospitalier Universitaire de Caen Normandie, Centre Hospitalier Universitaire de Reims, Centre Hospitalier Universitaire de Tours, Membrane Signalling and Inflammation in reperfusion Injuries
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,490
OpenAlex ID: W7235216843
